Impact of gene patents and licensing practices on access to genetic testing for hereditary hemochromatosis

Subhashini Chandrasekharan, Emily Pitlick, Christopher Heaney, Robert Cook-Deegan

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Hereditary hemochromatosis is an iron metabolism disorder that leads to excess iron buildup, especially in the heart, liver, and pancreas. Mutations in the HFE gene are the single most common cause of hereditary hemochromatosis, which can be treated effectively if diagnosed early. Patents cover the HFE gene, related proteins, screening methods, and testing kits. Most initial testing for hereditary hemochromatosis is biochemical, but HFE deoxyribonucleic acid testing or genotyping is used to confirm a diagnosis of inherited hemochromatosis. Concerns over patents covering HFE testing emerged in 2002, when scholars argued that exclusive licensing and the patent-enabled sole provider model then in place led to high prices and limited access. Critics of the sole provider model noted that the test was available at multiple laboratories before the enforcement of patents. By 2007, however, Bio-Rad Limited, acquired the key intellectual property and sublicensed it widely. In part because of broad, nonexclusive licensing, there are now multiple providers and testing technologies, and research continues. This case study illustrates how both changes in intellectual property ownership and evolving clinical utility of HFE genetic testing in the last decade have effected the licensing of patents and availability of genetic testing.

Original languageEnglish (US)
JournalGenetics in Medicine
Volume12
Issue number4 SUPPL.
DOIs
StatePublished - Apr 2010
Externally publishedYes

Fingerprint

Hemochromatosis
Patents
Genetic Testing
Licensure
Intellectual Property
Genes
Iron Metabolism Disorders
Ownership
Pancreas
Iron
Technology
Mutation
Liver
DNA
Research
Proteins

Keywords

  • Genetic testing
  • Hemochromatosis
  • HFE
  • Intellectual property
  • Patents

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Impact of gene patents and licensing practices on access to genetic testing for hereditary hemochromatosis. / Chandrasekharan, Subhashini; Pitlick, Emily; Heaney, Christopher; Cook-Deegan, Robert.

In: Genetics in Medicine, Vol. 12, No. 4 SUPPL., 04.2010.

Research output: Contribution to journalReview article

Chandrasekharan, Subhashini ; Pitlick, Emily ; Heaney, Christopher ; Cook-Deegan, Robert. / Impact of gene patents and licensing practices on access to genetic testing for hereditary hemochromatosis. In: Genetics in Medicine. 2010 ; Vol. 12, No. 4 SUPPL.
@article{2163fe1a74534f49ba2572c5043cc5e7,
title = "Impact of gene patents and licensing practices on access to genetic testing for hereditary hemochromatosis",
abstract = "Hereditary hemochromatosis is an iron metabolism disorder that leads to excess iron buildup, especially in the heart, liver, and pancreas. Mutations in the HFE gene are the single most common cause of hereditary hemochromatosis, which can be treated effectively if diagnosed early. Patents cover the HFE gene, related proteins, screening methods, and testing kits. Most initial testing for hereditary hemochromatosis is biochemical, but HFE deoxyribonucleic acid testing or genotyping is used to confirm a diagnosis of inherited hemochromatosis. Concerns over patents covering HFE testing emerged in 2002, when scholars argued that exclusive licensing and the patent-enabled sole provider model then in place led to high prices and limited access. Critics of the sole provider model noted that the test was available at multiple laboratories before the enforcement of patents. By 2007, however, Bio-Rad Limited, acquired the key intellectual property and sublicensed it widely. In part because of broad, nonexclusive licensing, there are now multiple providers and testing technologies, and research continues. This case study illustrates how both changes in intellectual property ownership and evolving clinical utility of HFE genetic testing in the last decade have effected the licensing of patents and availability of genetic testing.",
keywords = "Genetic testing, Hemochromatosis, HFE, Intellectual property, Patents",
author = "Subhashini Chandrasekharan and Emily Pitlick and Christopher Heaney and Robert Cook-Deegan",
year = "2010",
month = "4",
doi = "10.1097/GIM.0b013e3181d7acb0",
language = "English (US)",
volume = "12",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Impact of gene patents and licensing practices on access to genetic testing for hereditary hemochromatosis

AU - Chandrasekharan, Subhashini

AU - Pitlick, Emily

AU - Heaney, Christopher

AU - Cook-Deegan, Robert

PY - 2010/4

Y1 - 2010/4

N2 - Hereditary hemochromatosis is an iron metabolism disorder that leads to excess iron buildup, especially in the heart, liver, and pancreas. Mutations in the HFE gene are the single most common cause of hereditary hemochromatosis, which can be treated effectively if diagnosed early. Patents cover the HFE gene, related proteins, screening methods, and testing kits. Most initial testing for hereditary hemochromatosis is biochemical, but HFE deoxyribonucleic acid testing or genotyping is used to confirm a diagnosis of inherited hemochromatosis. Concerns over patents covering HFE testing emerged in 2002, when scholars argued that exclusive licensing and the patent-enabled sole provider model then in place led to high prices and limited access. Critics of the sole provider model noted that the test was available at multiple laboratories before the enforcement of patents. By 2007, however, Bio-Rad Limited, acquired the key intellectual property and sublicensed it widely. In part because of broad, nonexclusive licensing, there are now multiple providers and testing technologies, and research continues. This case study illustrates how both changes in intellectual property ownership and evolving clinical utility of HFE genetic testing in the last decade have effected the licensing of patents and availability of genetic testing.

AB - Hereditary hemochromatosis is an iron metabolism disorder that leads to excess iron buildup, especially in the heart, liver, and pancreas. Mutations in the HFE gene are the single most common cause of hereditary hemochromatosis, which can be treated effectively if diagnosed early. Patents cover the HFE gene, related proteins, screening methods, and testing kits. Most initial testing for hereditary hemochromatosis is biochemical, but HFE deoxyribonucleic acid testing or genotyping is used to confirm a diagnosis of inherited hemochromatosis. Concerns over patents covering HFE testing emerged in 2002, when scholars argued that exclusive licensing and the patent-enabled sole provider model then in place led to high prices and limited access. Critics of the sole provider model noted that the test was available at multiple laboratories before the enforcement of patents. By 2007, however, Bio-Rad Limited, acquired the key intellectual property and sublicensed it widely. In part because of broad, nonexclusive licensing, there are now multiple providers and testing technologies, and research continues. This case study illustrates how both changes in intellectual property ownership and evolving clinical utility of HFE genetic testing in the last decade have effected the licensing of patents and availability of genetic testing.

KW - Genetic testing

KW - Hemochromatosis

KW - HFE

KW - Intellectual property

KW - Patents

UR - http://www.scopus.com/inward/record.url?scp=77951470753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951470753&partnerID=8YFLogxK

U2 - 10.1097/GIM.0b013e3181d7acb0

DO - 10.1097/GIM.0b013e3181d7acb0

M3 - Review article

VL - 12

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 4 SUPPL.

ER -